Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1369

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 6
Chunk 1369
---
Kim
currently serves as the Head of Marketing, Private Equity Funds at Korea Daesung Asset Management Co., Ltd. the position held by him since
January 2021. Prior to that, Mr. Kim has spent approximately 11 years working in different positions with Samsung Group’s
financial business arms which include Samsung Fire and Marine Non-Life Insurance (Corporate Planning and Strategy Department) and
Samsung Asset Management (as Chief Strategy Officer and the Regional Managing Director in Beijing, China). Prior to his tenure with Samsung
Group, Mr. Kim spent about 6 years working as management consultant at Accenture and A.T. Kearney. Serving as management
consultant, Mr. Kim has conducted a number of strategic consulting projects for the clients in financial industry such as major banks,
brokers, insurances and credit card companies in Korea. Mr. Kim has passed the High-Level Government Official Examination in
1993 which led him to his government-sector career from 1994 through 2001 during which time he was able to participate in global
trade negotiation projects in the field of agricultural goods, and he also joined the Korean National Negotiation Team to represent South
Korea in multilateral trade communications such as WTO, APEC and Bilateral Trade Consultations (FTA). Mr. Kim earned his MBA degree
from Georgetown University in 2001, and his M.A. (Public Policy) and B.S. (International Economics) from Seoul National University. Mr. Kim
is well qualified to serve as a Director because of his extensive experience in both legal and investment sectors across various asset
classes, demonstrating significant expertise in capital market.

Hyuk Joo Jee became a Director of the Company upon the Closing
of the Business Combination. Mr. Jee has served as a Special Advisor to Chairman at DongKoo Bio Pharma Co., Ltd., a public company
in Korea, since January 2024. Prior to joining DongKoo Bio Pharma, Mr. Jee served with HLB Co., Ltd., also a publicly-listed biopharmaceutical
company in Korea, as Chief Operating Officer and the Head of Corporate Private Equity leading the firm’s investments and resource
allocations over a global pipeline of clinical-stage oncology programs from August 2018 through December 2023. During his
tenure at HLB, Mr. Jee led the firm’s global IR, M&As and strategic investment activities. Prior